MetaCap

BlossomHill Therapeutics (BLSM) vs Helus Pharma (HELP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Helus Pharma is the larger company by market cap ($487.7 million vs $461.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BLSM-9.31%HELP-47.37%
+73%+10%-53%
Aug 7, 20261 yearNov 20, 2026
BLSM-9.31%HELP-47.37%
+66%+7%-53%
Aug 3, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BLSM versus HELP key metrics
MetricBLSMHELP
Share price$14.51$6.11
Market cap$461.20M$487.68M
1-day change+0.69%-9.88%
YTD return—-25.31%
1-year return—+9.30%
5-year return—-88.09%
EPS (TTM)$-10.38$-4.25
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$27.99$15.15
52-week low$11.02$3.76
Distance from 52-week high-48.16%-59.67%
Analyst consensusstrong_buynone
Avg. price target upside+143.97%+564.81%
Average volume193.15K1.83M
Shares outstanding31.78M79.81M
Employees69100
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About BlossomHill Therapeutics

BLSM stock →

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

About Helus Pharma

HELP stock →

Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions.

Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees

BLSM vs HELP FAQ

Which is bigger, BlossomHill Therapeutics or Helus Pharma?

Helus Pharma (HELP) is larger, with a market capitalization of $487.68M compared with $461.20M for BlossomHill Therapeutics (BLSM).

Are BlossomHill Therapeutics and Helus Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons